Coverage is focused primarily on SMID-cap immuno-oncology under lead analyst Daina Graybosch. Oncology subsector expertise includes ADCs & drug conjugates, cell therapy, cytokines, immune cell engagers and bispecifics, and other novel IO modalities; secondary therapeutic area focus on immunology & inflammation (I&I)Current coverage (lead covering analyst): PYXSCurrent coverage (under Daina Graybosch): ACLX, AFMD, BNTX, BOLT, CGEN, FATE, GILD, IPHA, HOWL, ITOS, IPSC, LVTX, MOLN, MRK, NKTX, RCUS, TSBX, TSVTFormer coverage: FSTX, GNCA, NKTR, SBTX

Coverage comprised of mostly SMID-cap biotechnology companies under lead analyst David Nierengaraten. Primary focus on oncology, immunology/inflammation, rare disease, and gene and cell therapy:Covered names: AGTC, ANAB, ARAV, ARDX, ARGX, AVRO, BEAM, BLUE, BOLD, BPMC, CMTA, ECYT, EPZM, FATE, FENC, FRLN, FUSN, GBIO, GTHX, INZY, IRWD, ISEE, ITOS, JUNO, KITE, KPTI, KNSA, MGNX, MGTA, MRSN, MRUS, MYOK, NITE, NOVN, NTLA, NVCR, ONCE, ORTX, PRTA, RARE, SRRK, STML, STRO, SWTX, SYRS, SYBX, TCRR, TPTX, TSRO, UMRX, VYGR, XNCR, YMAB

Engaged as a strategy consultant for a major tertiary care center in the greater Boston area regarding the growth of its neurosurgical department.

Research focus: the relationship between c-Myc, PINK1, and autophagy in cancer cells; the extra-mitochondrial effects of OPA1; the relationship between c-Myc and mitofusins; the relationship between N-Myc and neuroblastoma.